

CLAIMS

1. A composition, characterized in that it comprises at least one antibody chosen from the group (i) of
5 anti-MSRV/HERV-W Env-SU antibodies or from the group (ii) of anti-TLR4 antibodies, capable of binding specifically to the soluble fraction of the MSRV/HERV-W Env protein or to the TLR4 receptor for the soluble fraction of the MRSV/HERV-W Env protein, and a
10 pharmaceutically acceptable carrier; said antibodies inhibiting the pro-inflammatory cascade induced by the activation of MSRV/HERV-W.
2. The composition as claimed in claim 1,
15 characterized in that it comprises a pharmaceutically acceptable vector.
3. The composition as claimed in claim 1 or claim 2, characterized in that it comprises at least one anti-
20 MSRV/HERV-W Env-SU antibody of group (i) and at least one anti-TLR4 antibody of group (ii).
4. The composition as claimed in one of claims 1 to 3, characterized in that the anti-HERV-W Env-SU
25 antibody of group (i) is chosen from the antibodies 3B2H4, 13H5A5 and 3H10F10 and the anti-TLR4 antibody of group (ii) is the antibody HTA125.
5. The use of at least one antibody chosen from the
30 group (i) of anti-MSRV/HERV-W Env-SU antibodies or from the group (ii) of anti-TLR4 antibodies, capable of binding specifically to the soluble fraction of the MSRV/HERV-W Env protein or to the TLR4 receptor for the soluble fraction of the MSRV/HERV-W Env protein, for
35 the preparation of a medicament; said antibodies inhibiting the pro-inflammatory cascade induced by the activation of MSRV/HERV-W.

6. The use, as claimed in claim 5, of at least one anti-MSRV/HERV-W Env-SU antibody of group (i) and of at least one anti-TLR4 antibody of group (ii).

5

7. The use as claimed in either one of claims 5 and 6, in which the anti-HERV-W Env-SU antibody of group (i) is chosen from the antibodies 3B2H4, 13H5A5 and 3H10F10 and the anti-TLR4 antibody of group (ii) is the antibody HTA125.

10

8. The use as claimed in claim 7, for the treatment of a pathology associated with MSRV/HERV-W.

9. The use as claimed in claim 7, in which the pathology is multiple sclerosis or schizophrenia.

15

10. An antibody chosen from the antibodies 3B2H4, 13H5A5 and 3H10F10.

20

11. The use of MSRV/HERV-W Env-SU for determining the state of reactivity of the blood mononuclear cells of patients suffering from multiple sclerosis or from schizophrenia, by assaying cytokines chosen from IL-6, IL12-p40 and TNF- α .

25